Kamada Ltd.: Pivotal Phase III Data Confirms Efficacy and Safety of Intravenous Alpha-1 Antitrypsin

NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada (www.kamada.com), a biopharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today that it has completed the final analysis of its US Phase III trial with intravenous Alpha-1 Antitrypsin (AAT), for hereditary AAT deficiency. In keeping with headline results announced in April, the study met its primary endpoint. The company has now officially completed the clinical stage of this product's development, high safety profile sided to meeting the primary endpoint were determined.